TURP bests PAE for treating BPH

  • Jiang YL & al.
  • BMC Urol
  • 28 Jan 2019

  • curated by Craig Hicks
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Transurethral resection of the prostate (TURP) is superior to prostatic artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH).

Why this matters

  • There are no standards or guidelines for evaluating the clinical efficacy of TURP and PAE for treating BPH.

Study design

  • Researchers analyzed 4 studies comparing the efficiency and safety of TURP with that of PAE (N=506).
  • Funding: None disclosed.

Key results

  • Pooled data showed that peak urinary flow rate was significantly higher in patients who underwent TURP vs those who underwent PAE:
    • Weight mean difference (WMD), 4.66 (95% CI, 2.54-6.79; P<.05>
  • Postoperative QoL was lower for TURP than PAE:
    • WMD, −0.53 (95% CI, −0.88 to −0.18; P<.05>
  • Postoperative prostate volume was significantly smaller for TURP than PAE:
    • WMD, −8.26 (95% CI, −12.64 to −3.88; P<.05>
  • Operative time was significantly shorter for TURP than PAE:
    • WMD: −10.55 (95% CI, −16.92 to −4.18; P=.001).

Limitations

  • Only 2 studies were randomized controlled trials.
  • Studies had small sample sizes and short follow-up periods that may have contributed to worse outcomes for PAE.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit